Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yao-Yu Hsieh

Showing results (31-40 of 48) with videos related to

Pageof 5
Sort By:
Oncotarget|September 8, 2018
Correction: Loss of EGFR signaling-regulated miR-203 promotes prostate cancer bone metastasis and tyrosine kinase inhibitors resistanceMan Kit Siu, Wassim Abou-Kheir, Juan Juan Yin, et al.
Japanese Journal of Clinical Oncology|January 10, 2018
A Phase I/II study of the combination of lapatinib and oral vinorelbine in HER2-positive metastatic breast cancerTom Wei-Wu Chen, Dah-Cherng Yeh, Tsu-Yi Chao, et al.
European Journal of Haematology|December 16, 2010
Effect of allogeneic hematopoietic stem cell transplantation from matched siblings or unrelated donors during the first complete remission in patients with cytogenetically normal acute myeloid leukemiaYao-Yu Hsieh, Ying-Chung Hong, Liang-Tsai Hsiao, et al.
Asian Journal of Surgery|September 5, 2024
The clinicopathological significance and prognostic impact of 14-3-3σ/stratifin expression on patients with surgically resectable intrahepatic cholangiocarcinomaSu-Hong Wang, Yao-Yu Hsieh, Khaa Hoo Ong, et al.
Journal of Hepatocellular Carcinoma|December 1, 2025
Machine Learning-Based Survival Analysis for Patients Receiving Lenvatinib for Unresectable Hepatocellular CarcinomaChien-Hung Lu, Ching-Wen Chang, San-Chi Chen, et al.
Oncology Letters|November 29, 2023
LAMC2 is a potential prognostic biomarker for cholangiocarcinomaKhaa Hoo Ong, Yao-Yu Hsieh, Hong-Yue Lai, et al.
European Journal of Cancer (Oxford, England : 1990)|January 23, 2026
SLOG versus modified FOLFIRINOX as first-line treatment for advanced pancreatic cancer: A randomized phase II trial (TCOG T5217)Nai-Jung Chiang, Yung-Yeh Su, I-Wei Ho, et al.
Scientific Reports|October 14, 2023
Cartilage oligomeric matrix protein overexpression is an independent poor prognostic indicator in patients with intrahepatic cholangiocarcinomaKhaa Hoo Ong, Yao-Yu Hsieh, Hong-Yue Lai, et al.
Frontiers in Oncology|December 6, 2021
Taiwan Society of Colon and Rectal Surgeons Consensus on mCRC TreatmentHong-Hwa Chen, Tao-Wei Ke, Ching-Wen Huang, et al.
Nutrients|July 14, 2023
Efficacy and Safety of a Parenteral Nutrition Program for Patients with <i>RAS</i> Wild-Type Metastatic Colorectal Cancer Administered First-Line Cetuximab Plus Chemotherapy: A Propensity Score Matching StudyYu-Tang Chang, Chou-Chen Chen, Shih-Ching Chang, et al.
Pageof 5

Showing results (31-40 of 48) with videos related to

Sort By:
Pageof 5
Oncotarget|September 8, 2018
Correction: Loss of EGFR signaling-regulated miR-203 promotes prostate cancer bone metastasis and tyrosine kinase inhibitors resistanceMan Kit Siu, Wassim Abou-Kheir, Juan Juan Yin, et al.
Japanese Journal of Clinical Oncology|January 10, 2018
A Phase I/II study of the combination of lapatinib and oral vinorelbine in HER2-positive metastatic breast cancerTom Wei-Wu Chen, Dah-Cherng Yeh, Tsu-Yi Chao, et al.
European Journal of Haematology|December 16, 2010
Effect of allogeneic hematopoietic stem cell transplantation from matched siblings or unrelated donors during the first complete remission in patients with cytogenetically normal acute myeloid leukemiaYao-Yu Hsieh, Ying-Chung Hong, Liang-Tsai Hsiao, et al.
Asian Journal of Surgery|September 5, 2024
The clinicopathological significance and prognostic impact of 14-3-3σ/stratifin expression on patients with surgically resectable intrahepatic cholangiocarcinomaSu-Hong Wang, Yao-Yu Hsieh, Khaa Hoo Ong, et al.
Journal of Hepatocellular Carcinoma|December 1, 2025
Machine Learning-Based Survival Analysis for Patients Receiving Lenvatinib for Unresectable Hepatocellular CarcinomaChien-Hung Lu, Ching-Wen Chang, San-Chi Chen, et al.
Oncology Letters|November 29, 2023
LAMC2 is a potential prognostic biomarker for cholangiocarcinomaKhaa Hoo Ong, Yao-Yu Hsieh, Hong-Yue Lai, et al.
European Journal of Cancer (Oxford, England : 1990)|January 23, 2026
SLOG versus modified FOLFIRINOX as first-line treatment for advanced pancreatic cancer: A randomized phase II trial (TCOG T5217)Nai-Jung Chiang, Yung-Yeh Su, I-Wei Ho, et al.
Scientific Reports|October 14, 2023
Cartilage oligomeric matrix protein overexpression is an independent poor prognostic indicator in patients with intrahepatic cholangiocarcinomaKhaa Hoo Ong, Yao-Yu Hsieh, Hong-Yue Lai, et al.
Frontiers in Oncology|December 6, 2021
Taiwan Society of Colon and Rectal Surgeons Consensus on mCRC TreatmentHong-Hwa Chen, Tao-Wei Ke, Ching-Wen Huang, et al.
Nutrients|July 14, 2023
Efficacy and Safety of a Parenteral Nutrition Program for Patients with <i>RAS</i> Wild-Type Metastatic Colorectal Cancer Administered First-Line Cetuximab Plus Chemotherapy: A Propensity Score Matching StudyYu-Tang Chang, Chou-Chen Chen, Shih-Ching Chang, et al.
Pageof 5